Our findings provide insight into how the p53/lincRNA-p21/STAT3 axis contributes to HNSCC development and indicate that lincRNA-p21 may serve as a novel therapeutic target for HNSCC. The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.